ESMO - Eur. Oncology· @myESMO · X·· 2 天前评分70
正文 · 原文
#ESMO26: Data from the MOIO trial were inconclusive regarding whether de-escalating #immunotherapy is beneficial after previous response to 6-month #ImmuneCheckpointInhibitor therapy in patients with a range of advanced #SolidTumours.
#InsightsbyESMO ➡️https://ow.ly/9WhK51002S2
26 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
De-escalating IO drugs (MOIO trial): Interim pharmacokinetic and immunomonitoring analysis
https://esmocongress.esmo.org来源：ESMO - Eur. Oncology · x.com